Mecasermin (Increlex▼): risk of benign and malignant neoplasia

An EU review has found an increased incidence of benign and malignant tumours in children and adolescents receiving mecasermin post-marketing. This alert advises healthcare professionals to permanently discontinue mecasermin if a benign or malignant neoplasm develops.


Medicines and Healthcare products Regulatory Agency